Skip to main content

Table 1 Kidney gene expression

From: JAK3-STAT pathway blocking benefits in experimental lupus nephritis

Gene Control CYP MMF CP p Value
C3 4.8 ± 1.6 1.61 ± 0.4a 1.67 ± 0.2a 2.1 ± 0.4a 0.02
CCL2 3.5 ± 0.9 1.35 ± 0.4 2.7 ± 0.9 2 ± 0.6 NS
CCL5 1.4 ± 0.4 0.43 ± 0.1 0.9 ± 0.2 0.9 ± 0.4 NS
CD40L 1.2 ± 0.3 0.4 ± 0.1a,b 0.8 ± 0.2 0.1 ± 0.1a,b 0.0017
IL2 1.3 ± 0.4 0.5 ± 0.2a 0.3 ± 0.1a 0.2 ± 0.1a 0.02
IL6 3.3 ± 1.7 0.3 ± 0.0a 0.9 ± 0.3a 0.5 ± 0.1a 0.03
TLR9 1.5 ± 0.1 0.3 ± 0.1a 0.5 ± 0.1a 0.6 ± 0.1a 0.0001
VCAM1 1.2 ± 0.1 0.8 ± 0.2 0.6 ± 0.1 0.9 ± 0.1 NS
STAT1 2.01 ± 0.2 0.66 ± 0.3a 0.71 ± 0.1a 0.48 ± 0.1a 0.0001
STAT2 1.86 ± 0.1 0.82 ± 0.1a 0.86 ± 0.1a 0.57 ± 0.1a 0.0001
STAT3 2.14 ± 0.4 0.92 ± 0.1a 0.99 ± 0.2 0.98 ± 0.1a 0.016
STAT4 2.23 ± 0.3 0.42 ± 0.1a 0.51 ± 0.1a 0.21 ± 0.1a 0.0001
STAT5a 1.42 ± 0.3 0.64 ± 0.1a 0.59 ± 0.1a 0.62 ± 0.1a 0.021
  1. Abbreviations: C3, complement component 3, CCL chemokine (C-C motif) ligand, CP CP-690,550, CYP cyclophosphamide, IL interleukin, MMF mycophenolate mofetil, NS not significant, STAT signal transducer and activator of transcription, TLR Toll-like receptor, VCAM1 vascular cell adhesion molecule 1
  2. Data presented are fold changes in 18S ribosomal RNA, house keeping gene for random target polymerase chain reaction
  3. aCompared with control
  4. bCompared with MMF